Latest Thesis
Merck: Keytruda scale still has to bridge the patent and pipeline test
Merck reported FY2025 revenue of $65.0 billion and 2026 Q1 revenue of $16.3 billion. The thesis depends on Keytruda durability, pipeline conversion, R&D productivity, acquisition discipline and cash conversion.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
Recent Reports
Compact report index for this company.
ReportTypeUpdatedReadActions
Merck: Keytruda scale still has to bridge the patent and pipeline testMerck reported FY2025 revenue of $65.0 billion and 2026 Q1 revenue of $16.3 billion. The thesis depends on Keytruda durability, pipeline conversion, R&D productivity, acquisition discipline and cash conversion.NYSEMay 19, 2026Research reportReadSlides